NCT06004960View on ClinicalTrials.gov

A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 20, 2014

Primary Completion Date

December 5, 2014

Study Completion Date

December 5, 2014

Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
DRUG

[14C]CCX168

Administered orally.

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY